Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in New York: - Hematology Oncology Associates of Central New York-Auburn — Auburn, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Glens Falls Hospital — Glens Falls, New York
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- North Shore University Hospital — Manhasset, New York
- Long Island Jewish Medical Center — New Hyde Park, New York
- Mount Sinai Hospital — New York, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in New York: - Glens Falls Hospital — Glens Falls, New York
- University of Rochester — Rochester, New York
- Wilmot Cancer Institute at Webster — Webster, New York
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in New York: - Albany Medical Center — Albany, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- New York Presbyterian - Weill Cornell — New York, New York
- University of Rochester Medical Center — Rochester, New York
- Einstein-Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Sites in New York: - Ascentage Investigative Site #1068 — Rochester, New York
- Ascentage Investigative Site #1053 — Shirley, New York
- Ascentage Investigative Site #1160 — Stony Brook, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in New York: - Columbia University Medical Center — New York, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in New York: - New York Oncology Hematology, P.C. ( Site 0069) — Albany, New York
- Roswell Park Cancer Institute ( Site 0023) — Buffalo, New York
- RPCI Oncology, PC- Northtowns ( Site 0061) — Williamsville, New York
Phase 3 Recruiting Network
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…
Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Sites in New York: - Albany Medical Center — Albany, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in New York: - Icahn School of Medicine at Mount Sinai /ID# 266328 — New York, New York
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Sites in New York: - University of Rochester Medical Center (URMC) — Rochester, New York
- Stony Brook University (SBU) - Cancer Center — Stony Brook, New York
Phase 3 Recruiting Industry
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Sites in New York: - Quetzal Site 4 — Buffalo, New York
- Quetzal Site 2 — The Bronx, New York
Phase 3 Recruiting Industry
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemot…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06051409
Sites in New York: - Ascentage Investigative Site #1160 — Stony Brook, New York
- Ascentage Investigative Site #1151 — The Bronx, New York
Phase 2, Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells t…
Sponsor: AbbVie
NCT ID: NCT07581002
Sites in New York: - Montefiore Medical Center - Moses Campus /ID# 279399 — The Bronx, New York
Phase 3 Recruiting Academic/Other
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive ti…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07223021
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- North Shore University Hospital — Manhasset, New York
- Mount Sinai Hospital — New York, New York
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- North Shore University Hospital — Manhasset, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Mount Sinai Hospital — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Rochester — Rochester, New York
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06672146
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Rochester — Rochester, New York
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting NIH
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- University of Rochester — Rochester, New York
- State University of New York Upstate Medical University — Syracuse, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07437950
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT ID: NCT06163430
Sites in New York: - Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …
Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York